191849-71-5

Basic information

• Product Name: 3-ETHOXYBENZENE-1,2-DIAMINE
• Synonyms: 3-ETHOXYBENZENE-1,2-DIAMINE
• CAS NO: 191849-71-5
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.2
• Mol File: 191849-71-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-ETHOXYBENZENE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-ETHOXYBENZENE-1,2-DIAMINE(191849-71-5)
• EPA Substance Registry System: 3-ETHOXYBENZENE-1,2-DIAMINE(191849-71-5)

Safety Data

• Hazardous Substances Data: 191849-71-5(Hazardous Substances Data)

Upstream product

• 4280-24-4 (2,3-dinitrophenyl)ethylether 
• 6036-46-0 2-amino-3-ethoxynitrobenzene 
• 66-56-8 2,3-dinitrophenol 

Downstream Products

• 18514-74-4 5-Ethoxy-chinoxalin 

Relevant articles and documents

Design, Synthesis, Biological Evaluation, and Molecular Modeling of 2-Difluoromethylbenzimidazole Derivatives as Potential PI3Kα Inhibitors

PI3Kα is one of the potential targets for novel anticancer drugs. In this study, a series of 2-difluoromethylbenzimidazole derivatives were studied based on the combination of molecular modeling techniques 3D-QSAR, molecular docking, and molecular dynamic

A model D - amino acid oxidase inhibitor and its preparation and application

The invention provides a novel D- amino acid oxidase inhibitor and a preparation and application thereof. In particular, the invention discloses derivatives of quinoxaline-2,3-diketone, which has a novel structure shown in formula A, as well as a preparation method thereof and an application as an inhibitor of D-amino acid oxidase (DAAO). The compound provided by the invention shows excellent effects of analgesia and blocking morphine analgesia tolerance, and has application value for analgesia, treating opiate drug tolerance, and anti-schizophrenia.

Synthesis and biological evaluation of novel analogues of the pan class i phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(Difluoromethyl)-1-[4,6-di(4- morpholinyl)-1,3,5-triazin-2-yl]-1 H -benzimidazole (ZSTK474)

A structure-activity relationship (SAR) study of the pan class I PI 3-kinase inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2- yl]-1H-benzimidazole (ZSTK474) identified substitution at the 4 and 6 positions of the benzimidazole ring as having significant effects on the potency of substituted derivatives. The 6-amino-4-methoxy analogue displayed a greater than 1000-fold potency enhancement over the corresponding 6-aza-4-methoxy analogue against all three class Ia PI 3-kinase enzymes (p110α, p110β, and p110δ) and also displayed significant potency against two mutant forms of the p110α isoform (H1047R and E545K). This compound was also evaluated in vivo against a U87MG human glioblastoma tumor xenograft model in Rag1 -/- mice, and at a dose of 50 mg/kg given by ip injection at a qd ?- 10 dosing schedule it dramatically reduced cancer growth by 81% compared to untreated controls.

SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY

Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with

BRIDGED SIX-MEMBERED RING COMPOUNDS

The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.